Format

Send to

Choose Destination

A pilot study of nadolol for overt aggression in developmentally delayed individuals.

Author information

1
Department of Psychiatry/Room S7-828, University of Massachusetts Medical Center, Worcester 01655, USA.

Abstract

OBJECTIVE:

The aim of this preliminary pilot study was to investigate the safety and efficacy of open-label nadolol as an adjunctive pharmacological treatment for aggression and/or inattention/overactivity in a developmentally delayed child, adolescent, and young adult population.

METHOD:

Twelve subjects enrolled and completed (mean age 13.8 years, range 9 through 24) a 5-month, open, prospective protocol of nadolol (mean dose 109 mg, range 30 through 220 mg) with systematic baseline and outcome evaluations and weekly clinical assessment.

RESULTS:

All subjects were developmentally delayed and most were cognitively delayed. Ten subjects (83%) showed clinical improvement while receiving nadolol. Significant improvements were noted on observer-rated overt categorical aggression, severity of illness, and global impressions of improvement. No significant effects were found for inattention/overactivity. Nadolol was well tolerated, with few side effects.

CONCLUSIONS:

Overt categorical aggression presenting in developmentally delayed children, adolescents, and young adults may respond to nadolol treatment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center